No Data
No Data
The medical instruments sector of the A-share market is declining, and Improve Medical Instruments has hit the limit down.
On September 18th, Intco Medical Technology and Improve Medical Instruments both hit the limit down, with Guanhao Biotech, Zhonghong Medical, Huada Intelligent Creation, Beijing Leadman Biochemistry and other companies leading the decline.
Improve Medical Instruments (300030.SZ): Currently, the main products are vacuum blood collection systems, not involving foreign medical investment or hospital investment
Gelonghui September 12th | Improve medical instruments (300030.SZ) accepted investor research on September 12, 2024, regarding 'Currently, the country has opened up foreign medical investment, hospital investment, what impact does this have on your company? As the major shareholder, what development suggestions does Geli have?'. The company stated that its main products are vacuum blood collection systems, and do not involve foreign medical investment or hospital investment.
Express News | Improve Medical Instruments: There is no new progress in the investigation of the detained chairman. The business of the subsidiary does not involve human stem cells.
Double board Improve Medical Instruments (300030.SZ): Subsidiary Hangzhou Kangdaisi Rui Biotechnology's main business does not include aspects such as human stem cells.
Improve Medical Instruments (300030.SZ) issued an announcement, the trading price of the company's stocks for two consecutive trading days (in 2024...
Improve Medical Instruments (300030.SZ): The business of holding subsidiary does not include the development and application of human stem cells, gene diagnosis and treatment technology.
On September 10, Global Medical (300030.SZ) announced a notice of abnormal fluctuations in stock trading. On September 7, 2024, the Ministry of Commerce, the National Health Commission, and the National Medical Products Administration issued a notice on expanding opening-up pilot work in the medical field. Starting from the date of this notice, foreign-invested enterprises are allowed to engage in the development and application of human stem cell, gene diagnosis, and treatment technology for product registration, listing, and production in China (Beijing) Free Trade Pilot Zone, China (Shanghai) Free Trade Pilot Zone, China (Guangdong) Free Trade Pilot Zone, and Hainan Free Trade Port. All approved
Express News | Two consecutive boards improve medical instruments: the business of its affiliated companies does not include the development and application of human stem cells, genetic diagnosis, and treatment technologies.
No Data
No Data